Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
Globe Newswire•04/11/2026•07:30 ET
0
Key Highlights
- ➤Harvard Bioscience (HBIO) management to participate in Canaccord Genuity forum November 11, 2026
- ➤John Duke to present on “Emerging Tools for Research and Biopharma Use Cases” panel
- ➤Management scheduled for one-on-one investor meetings at the forum
Expert Statements
John Duke, President and Chief Executive Officer of Harvard Bioscience
“Emerging Tools for Research and Biopharma Use Cases”
HOLLISTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer, will participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11(th), 2026.
Management will participate in one-on-one meetings, and John Duke will present on the “Emerging Tools for Research and Biopharma Use Cases” panel at 9:30am ET.
Get started
Create a free account to read the full story.